Novavax Phase 1 data shows coronavirus vaccine is safe and elicits an immune response
August 5, 2020. Summarized by summa-bot.
An employee works at the Stabilitech laboratory in Burgess Hill south east England, on May 15, 2020 where scientists are trying to develop an oral vaccine for the COVID-19 illness. - The scientists at Stabilitech are one of the teams attempting to develop a vaccine for COVID-19. Ingested in a capsule into the gut, Stabilitech's potential oral vaccine aims to prompt an immune response in mucosal cells in the respiratory system and elsewhere in the body. The firm believes that will be more effective in tackling respiratory illnesses like coronavirus. The British government is touting the country as a global leader in the big-money investment race to find a vaccine for COVID-19. (Photo by BEN STANSALL / AFP) / TO GO WITH AFP STORY BY JOE JACKSON (Photo by BEN STANSALL/AFP via Getty Images)
A third US company has released study results showing its coronavirus vaccine is safe and elicits an immune response.
(CNN)A third US company has released study results showing its coronavirus vaccine is safe and elicits an immune response.
Novavax, Inc. released Phase 1 data Tuesday from 131 volunteers showing that after two doses of the vaccine, participants developed neutralizing antibodies at levels more than four times higher on average than the antibodies developed by people who had recovered from Covid-19.
Study participants received two doses of the vaccine at various dosages, both with and without an adjuvant -- a component to boost the immune system.
In the study, 12 monkeys received two doses of the vaccine and were then exposed to the virus that causes Covid-19.
One monkey, which received a low dose of the vaccine, briefly showed signs of infection in the lungs, but all signs of infection were gone two days later.
Novavax, Moderna, Pfizer, Johnson & Johnson, AstraZeneca and GlaxoSmithKline have all received funding from the federal government's Operation Warp Speed Program to develop Covid-19 vaccines, and two more unnamed companies will also receive funding, according to Moncef Slaoui, the head of the program.
Slaoui said he expects a vaccine to be available in December or January with enough doses for high-risk Americans, such as the elderly and those with underlying health problems.
He said he expects there to be enough vaccine for every American by the end of 2021.